Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2), encoded by the NFE2L2 gene, is the master transcriptional regulator of antioxidant response and cellular defense. Nrf2 coordinates the expression of over 200 genes involved in oxidative stress protection, metabolism, detoxification, and mitochondrial function. It is a critical therapeutic target for Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other neurodegenerative disorders.
| Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) | |
|---|---|
| Gene | [NFE2L2](/genes/nfe2l2) |
| UniProt ID | [Q16236](https://www.uniprot.org/uniprot/Q16236) |
| PDB Structure IDs | 2FLU, 3ZGC, 4UDD, 5CGJ |
| Molecular Weight | 60,300 Da (full-length) |
| Length | 605 amino acids |
| Subcellular Localization | Cytoplasm (basal); nucleus (active) |
| Protein Family | CNC-bZIP family (Nrf1, Nrf2, Nrf3, Bach1, Bach2) |
Nrf2 is a 605-amino acid transcription factor belonging to the CNC-bZIP family (Cap'n'Collar, alongside Nrf1, Nrf3, Bach1, Bach2). The protein contains 7 conserved Neh (Nrf2-ECH) domains that serve distinct functional roles:
| Domain | Amino Acids | Function |
|---|---|---|
| Neh1 | 86-163 | CNC-bZIP for DNA binding, heterodimerization with small Maf |
| Neh2 | 165-318 | Transactivation domain, contains KEAP1-binding motifs (ETGE, DLG) |
| Neh3 | 323-430 | Transactivation domain, recruits coactivators |
| Neh4 | 431-500 | Transactivation domain, recruits coactivators ( CBP/p300) |
| Neh5 | 501-561 | Transactivation domain, acidic region |
| Neh6 | 562-605 | Multidomain, regulates nuclear accumulation |
| Neh7 | 1-85 | BTB-like domain, negative regulation |
The Neh2 domain contains two key motifs that mediate KEAP1 interaction:
These motifs are essential for Nrf2 regulation under both basal and stress conditions.
Under basal (non-stress) conditions, Nrf2 is continuously sequestered in the cytoplasm by KEAP1 (Kelch-like ECH-associated protein 1), a cysteine-rich adaptor protein that functions as an E3 ubiquitin ligase substrate adaptor. KEAP1 targets Nrf2 for ubiquitination and proteasomal degradation, maintaining low Nrf2 levels (half-life ~15-30 minutes).
Upon oxidative stress, cysteine residues on KEAP1 (particularly C151, C273, C288) are oxidized, undergoing conformational changes that prevent Nrf2 ubiquitation. This releases Nrf2, which translocates to the nucleus.
In the nucleus, Nrf2 forms heterodimers with small Maf proteins (MAFK, MAFF, MAFG) and binds to the Antioxidant Response Element (ARE) sequence (5'-TGACnnnGC-3') in the promoter regions of target genes. This activates a battery of protective genes including:
Nrf2 regulates genes involved in:
Nrf2 activity declines with normal aging, and this decline is accelerated in neurodegenerative diseases. Several mechanisms contribute:
In Alzheimer's disease, Nrf2 signaling is impaired at multiple levels:
Nrf2 activation has shown benefit in AD models:
In Parkinson's disease, Nrf2 deficiency is particularly pronounced:
Nrf2 activators protect dopaminergic neurons in PD models:
In ALS, Nrf2 signaling is dysregulated:
Motor neurons show reduced Nrf2 expression, making them vulnerable to oxidative stress.
In Huntington's disease, Nrf2 activity is reduced:
Several classes of Nrf2 activators are in development:
| Compound | Class | Mechanism | Status | Disease |
|---|---|---|---|---|
| Bardoxolone methyl | CDDO-Im | Covalent KEAP1 inhibitor | Phase 2/3 | AD, CKD |
| Sulforaphane | Isothiocyanate | Covalent KEAP1 inhibitor | Phase 1/2 | PD, AD |
| Oltipraz | Dithiolopyrrolone | Nrf2 stabilizer | Phase 2 | Cancer |
| Dimethyl fumarate | Electrophile | KEAP1 modifier | Approved | MS |
| CDDO-Me | Synthetic triterpenoid | KEAP1 inhibitor | Phase 2 | AD |
BARDOXOLONE METHYL (CDDO-Im):
SULFORAPHANE:
┌──────────────────────────────────────┐
│ Nrf2 Activation │
└──────────────────────────────────────┘
│
┌───────────────────────────┬─┴─┬───────────────────────────┐
│ │ │ │
▼ ▼ ▼ ▼
┌─────────────────┐ ┌─────────────────┐ ┌─────────────────┐
│ NF-κB │◄──►│ Nrf2 │◄──►│ p53 │
│ inflammation │ │ antioxidant │ │ stress │
└─────────────────┘ └─────────────────┘ └─────────────────┘
│ │ │
▼ ▼ ▼
┌─────────────────┐ ┌─────────────────┐ ┌─────────────────┐
│ Pro-inflammatory│ │ Mitochondrial │ │ Cell cycle │
│ gene expression│ │ biogenesis │ │ regulation │
└─────────────────┘ └─────────────────┘ └─────────────────┘
| Model | Application | Reference |
|---|---|---|
| Nrf2 knockout mice | Nrf2 role in neurodegeneration | [5] |
| KEAP1 knockout mice | Constitutive Nrf2 activation | [6] |
| Transgenic Nrf2 overexpression | Nrf2 therapeutic potential | [7] |
| Conditional Nrf2 mice | Cell-type specific studies | [8] |
| SNP | Effect | Disease Association |
|---|---|---|
| rs6721961 (promoter) | Reduced Nrf2 expression | PD risk |
| rs2886158 | Altered Nrf2 activity | AD risk |
| rs2001823 | Modified oxidative stress response | ALS risk |
Johnson DA, et al. Keap1-Nrf2 pathway in Alzheimer's disease. 2024. ↩︎
Kim J, et al. Nrf2 dysfunction in Parkinson's disease models. 2023. ↩︎
Chen Q, et al. Nrf2-ARE signaling in ALS. 2022. ↩︎
Nakra T, et al. Nrf2 activators in clinical trials for AD. 2022. ↩︎
Kensler TW, et al. Nrf2 signaling in chemoprevention. 2007. ↩︎
Yamamoto M, et al. Nrf2 in oxidative stress and antioxidant response. 2018. ↩︎
Gao B, et al. Therapeutic targeting of Nrf2 in neurodegenerative diseases. 2021. ↩︎
Cuadrado A, et al. Targeting Nrf2 in disease. 2019. ↩︎
Sandberg M, et al. Nrf2 activators for neurodegenerative disease: clinical progress. 2024. ↩︎